The ELEVATE 1 clinical study is now closed and no longer enrolling. ELEVATE 2 is coming soon. Details about the ELEVATE 2 clinical study will be posted when they are available. Sign up for email updates here.
For physicians and others who would like more details about the ELEVATE 1 study, please visit www.ClinicalTrials.gov
RVT-1201, the ELEVATE Studies medicine, has the potential to be a new way to treat PAH. RVT-1201 uses a process called tryptophan hydroxylase (TPH) inhibition to reduce the amount of serotonin in the body. RVT-1201 is given orally as a tablet.
Why focus on reducing the amount of serotonin the body produces? Research has shown that increased levels of serotonin in the body can play a role in the development of PAH.
Serotonin is a substance that occurs naturally in your body. It is mainly found in your brain and digestive tract and appears to affect and/or regulate a number of body functions. It is thought that too much serotonin in the body may cause arteries in the lungs to narrow.
Doctors hope the ELEVATE Studies medicine, RVT-1201, can reduce the amount of serotonin affecting the lung arteries, without impacting serotonin in the brain, which may open the arteries to allow blood to flow more easily.
Artery of person with PAH
The ELEVATE Studies are sponsored by Altavant Sciences, GmbH (Altavant), a clinical stage biopharmaceutical company formed to advance promising therapies that treat rare respiratory diseases with an initial therapeutic focus on PAH. To learn more about Altavant, visit www.altavant.com.